Lupin Pharmaceuticals, Inc., the US subsidiary of Lupin, has entered into an agreement with Allergan, Inc. in the US to promote Zymar (gatifloxacin ophthalmic solution) in the market. The pediatric specialty formulation was approved by FDA in March 2003 as the first fourth generation ophthalmic fluoroquinolone to enter the market.

Zymar is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria.

Under the terms of the agreement, Lupin Pharmaceuticals’ pediatric sales force will promote Zymar to high volume pediatric prescribers. Lupin Pharmaceuticals has earlier created a dedicated national pediatric sales force in the US to promote its recently approved product Suprax.